[A comparative study of the pharmacokinetics and pharmacodynamics of bonnecor].
The pharmacokinetics and pharmacodynamics of bonnecor were studied simultaneously in animals with experimental arrhythmia. It was shown that irrespective of the animal species and individual features of the drug elimination kinetics the level of bonnecor concentration correlated with the antiarrhythmic effect. The data on the excretion of bonnecor and its metabolites in the urine in the dog and man were obtained. The decrease of bioavailability at oral administration of bonnecor was demonstrated to be related to its intensive conversion in metabolite M-I.
A P
AP
Rodionov
V V
VV
Lyskovtsev
N A
NA
Ignatova
E A
EA
Tolmacheva
E K
EK
Grigor'eva
G F
GF
Belinskiaia
B V
BV
Sheĭnberg
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D001682:Biological Availability; D005117:Cardiac Complexes, Premature / Q000188:drug therapy / Q000378:metabolism; D002415:Cats; D003984:Dibenzazepines / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D004285:Dogs; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D013610:Tachycardia / Q000188:drug therapy / Q000378:metabolism; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D003984:Dibenzazepines; C048166:tiracizine
Sravnitel'noe izuchenie farmakokinetiki i farmakodinamiki bonnekora.